F18-FDG PET/CT for detection of recurrent endometrial cancer

Objectives To evaluate the accuracy of positron emission tomography (PET) and computed tomography (CT) in the detection of recurrent endometrial cancer.

Methods Retrospective review of sequential [F¹⁸] fluorodeoxyglucose (FDG) PET/CT scans performed in the service for evaluation of recurrent endometrial adenocarcinoma of endometrioid type was done. Findings of PET/CT scans were compared with histological findings (following surgery or a biopsy) or concurrent CT scan. All patients had clinical follow-up for at least 6 months.

Results Thirty-three scans in 20 patients (median age: 60 years) were evaluated. Histological confirmation was available in 12 patients. In 8 patients, concurrent CT scan was the gold standard. Thirteen patients had positive PET scan (65%) and 7 (35%) had no evidence of recurrence by PET or other parameters. There were 19 true positive PET scans, and 12 true negative scans, confirmed by surgical biopsy or CT scan. There were two false positives by PET. The overall sensitivity and specificity was 100 % and 85.7%, respectively.

Conclusions FDG PET/CT is highly sensitive for detecting recurrent endometrial cancer in this subset of patients.